TY - JOUR
T1 - Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation
AU - Raynaud, Marc
AU - Aubert, Olivier
AU - Reese, Peter P.
AU - Bouatou, Yassine
AU - Naesens, Maarten
AU - Kamar, Nassim
AU - Bailly, Élodie
AU - Giral, Magali
AU - Ladrière, Marc
AU - Le Quintrec, Moglie
AU - Delahousse, Michel
AU - Juric, Ivana
AU - Basic-Jukic, Nikolina
AU - Gupta, Gaurav
AU - Akalin, Enver
AU - Yoo, Daniel
AU - Chin, Chen Shan
AU - Proust-Lima, Cécile
AU - Böhmig, Georg
AU - Oberbauer, Rainer
AU - Stegall, Mark D.
AU - Bentall, Andrew J.
AU - Jordan, Stanley C.
AU - Huang, Edmund
AU - Glotz, Denis
AU - Legendre, Christophe
AU - Montgomery, Robert A.
AU - Segev, Dorry L.
AU - Empana, Jean Philippe
AU - Grams, Morgan E.
AU - Coresh, Josef
AU - Jouven, Xavier
AU - Lefaucheur, Carmen
AU - Loupy, Alexandre
N1 - Funding Information:
We also thank INSERM – Action thématique incitative sur programme Avenir for their financial support. OA received a grant from the Fondation Bettencourt Schueller . MN received grants from the Research Foundation – Flanders (FWO; IWT.150199), the Flanders Innovation & Entrepreneurship of the Flemish Government (IWT.130758), and the Clinical Research Foundation of the University Hospitals Leuven.
Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2021/1
Y1 - 2021/1
N2 - Although the gold standard of monitoring kidney transplant function relies on glomerular filtration rate (GFR), little is known about GFR trajectories after transplantation, their determinants, and their association with outcomes. To evaluate these parameters we examined kidney transplant recipients receiving care at 15 academic centers. Patients underwent prospective monitoring of estimated GFR (eGFR) measurements, with assessment of clinical, functional, histological and immunological parameters. Additional validation took place in seven randomized controlled trials that included a total of 14,132 patients with 403,497 eGFR measurements. After a median follow-up of 6.5 years, 1,688 patients developed end-stage kidney disease. Using unsupervised latent class mixed models, we identified eight distinct eGFR trajectories. Multinomial regression models identified seven significant determinants of eGFR trajectories including donor age, eGFR, proteinuria, and several significant histological features: graft scarring, graft interstitial inflammation and tubulitis, microcirculation inflammation, and circulating anti-HLA donor specific antibodies. The eGFR trajectories were associated with progression to end stage kidney disease. These trajectories, their determinants and respective associations with end stage kidney disease were similar across cohorts, as well as in diverse clinical scenarios, therapeutic eras and in the seven randomized control trials. Thus, our results provide the basis for a trajectory-based assessment of kidney transplant patients for risk stratification and monitoring.
AB - Although the gold standard of monitoring kidney transplant function relies on glomerular filtration rate (GFR), little is known about GFR trajectories after transplantation, their determinants, and their association with outcomes. To evaluate these parameters we examined kidney transplant recipients receiving care at 15 academic centers. Patients underwent prospective monitoring of estimated GFR (eGFR) measurements, with assessment of clinical, functional, histological and immunological parameters. Additional validation took place in seven randomized controlled trials that included a total of 14,132 patients with 403,497 eGFR measurements. After a median follow-up of 6.5 years, 1,688 patients developed end-stage kidney disease. Using unsupervised latent class mixed models, we identified eight distinct eGFR trajectories. Multinomial regression models identified seven significant determinants of eGFR trajectories including donor age, eGFR, proteinuria, and several significant histological features: graft scarring, graft interstitial inflammation and tubulitis, microcirculation inflammation, and circulating anti-HLA donor specific antibodies. The eGFR trajectories were associated with progression to end stage kidney disease. These trajectories, their determinants and respective associations with end stage kidney disease were similar across cohorts, as well as in diverse clinical scenarios, therapeutic eras and in the seven randomized control trials. Thus, our results provide the basis for a trajectory-based assessment of kidney transplant patients for risk stratification and monitoring.
KW - end-stage renal disease
KW - glomerular filtration rate
KW - kidney function
KW - kidney transplantation
KW - mortality
KW - trajectories
UR - http://www.scopus.com/inward/record.url?scp=85098545308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098545308&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.07.025
DO - 10.1016/j.kint.2020.07.025
M3 - Article
C2 - 32781106
AN - SCOPUS:85098545308
SN - 0085-2538
VL - 99
SP - 186
EP - 197
JO - Kidney International
JF - Kidney International
IS - 1
ER -